<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This paper evaluates a recent study whereby a four-drug combination regimen adding bevacizumab to triplet fluorouracil, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and irinotecan chemotherapy is described for the first-line treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It extends the use of intensive medical treatments combining chemotherapy and the VEGF inhibitor bevacizumab, opening new perspectives for the design of four-drug intensive regimen-associating chemotherapy and targeted agents </plain></SENT>
<SENT sid="2" pm="."><plain>In the future, these four-drug intensive regimens should be further improved for efficacy:toxicity ratio and verification in randomized trials </plain></SENT>
</text></document>